1. Dy GK, Adjei AA. Novel targets for lung cancer therapy: Part I & II. J Clin Oncol. 2002. 20:2881–2894. 3016–3028.
2. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncology. 2002. 20:1s–13s.
3. Hirsch FR, Franklin WA, Bunn PA Jr. Expression of target molecules in lung cancer: Challenge for a new treatment paradigm. Semin Oncol. 2002. 29:Supplement 9. 2–8.
Article
4. Raben David, Helfrich Barbara A, Chan Dan, Johnson Gary, Bunn Paul A Jr, et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002. 29:Supplement 4. 37–46.
Article
5. Kim ES, Mauer AM, Fossella FV, Jamison TA, Kies MS, Herbst RS, et al. Proc ASCO #1168. A phase II study of Erbitux (IMC-225), an epidermal growth factor recepor(EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC). 2002.